Mounjaro is a registered trademark of Eli Lilly and Company. Mounjaro is the brand name for tirzepatide, a prescription medicine approved by the U.S. Food and Drug Administration to improve blood sugar control in adults and children age 10 and older with type 2 diabetes, along with diet and exercise. It is not a treatment for type 1 diabetes.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Important safety information
Mounjaro carries a boxed warning about the risk of thyroid C-cell tumors. Tirzepatide caused thyroid C-cell tumors in rats. It is not known whether Mounjaro causes these tumors, including medullary thyroid carcinoma, in people. Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other serious risks in the labeling include pancreatitis, low blood sugar when used with insulin or certain diabetes medicines, serious allergic reactions, acute kidney injury related to dehydration, severe stomach problems, gallbladder problems, and complications of diabetic retinopathy. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.
Read the complete official Mounjaro Prescribing Information and Medication Guide for the boxed warning, approved use, contraindications, warnings, interactions, and adverse reactions. A licensed clinician should review these risks in light of your health history and current medicines.
What kind of medicine is it?
The FDA labeling describes tirzepatide as both a glucose-dependent insulinotropic polypeptide, or GIP, receptor agonist and a glucagon-like peptide-1, or GLP-1, receptor agonist. These are hormone pathways involved in blood sugar regulation and appetite.
Mounjaro helps the body release insulin when blood sugar is elevated. It also lowers glucagon, a hormone that can raise blood sugar, and slows stomach emptying. Those effects are why a clinician needs to consider other medicines, digestive symptoms, and the timing of certain oral medicines.
This description explains the medicine's action. It does not predict how any one person will respond. Results and side effects vary, and no outcome can be guaranteed.
What is Mounjaro approved to treat?
Its FDA-approved use is to improve glycemic control in people age 10 and older with type 2 diabetes, together with diet and exercise. A clinician determines whether a person meets the clinical criteria and whether the expected benefits outweigh the risks.
People often encounter Mounjaro while searching for weight care. Body weight may change during diabetes treatment, but Mounjaro's approved indication is type 2 diabetes. A different brand containing tirzepatide has separate labeling for chronic weight management. Brand names, approved uses, and prescriptions should not be treated as interchangeable.
The reason for treatment matters to insurance plans, too. A health plan may require documentation of an approved diagnosis, prior authorization, or other criteria. Coverage and payment are determined by the plan, not by Body Good. A prescription does not guarantee coverage.
How is it taken?
According to the prescribing information, Mounjaro is injected under the skin once each week. The labeled starting dose is 2.5 mg once weekly for four weeks, followed by 5 mg once weekly. The starting dose is for treatment initiation and is not intended for blood sugar control. Any later increase depends on clinical response, tolerability, and the labeled schedule.
Do not start, stop, or change a dose based on an article. A clinician provides instructions for the specific prescription. The Medication Guide also explains what to do about a missed dose and how to store and handle the product.
Tell the clinician about all prescription medicines, over-the-counter products, vitamins, and supplements. This is especially important for insulin, medicines that can cause low blood sugar, and oral medicines whose absorption could be affected by slower stomach emptying. Also discuss pregnancy plans, anesthesia or deep sedation for a procedure, and any history of pancreas, kidney, gallbladder, eye, or serious digestive problems.
What happens before a prescription?
A licensed clinician reviews medical history, current medicines, allergies, relevant symptoms, and treatment goals. The clinician may request laboratory work or records when clinically appropriate. The answer may be that another approach is safer.
If prescribed, Mounjaro is dispensed by a state-licensed pharmacy pursuant to a valid prescription. It should not be offered as a product that anyone can simply buy after completing checkout. Legitimate care preserves the clinician's independent judgment and gives the patient a way to ask questions or report side effects.
Follow-up matters because blood sugar, other diabetes medicines, side effects, hydration, and dose changes may need review. Seek prompt medical help for symptoms identified as urgent in the Medication Guide, including signs of a serious allergic reaction or severe, persistent abdominal pain.
Costs and Body Good's role
The pharmacy charge for Mounjaro depends on the prescription, pharmacy, insurance benefit, and any savings program for which the patient is eligible. Lilly publishes current pricing and eligibility terms on its official savings and coverage page. Offers have restrictions, limits, and expiration dates and can change. They are not insurance.
Body Good provides clinical and administrative services, including clinical evaluation, follow-up, coverage support, and pharmacy routing when a prescription is written. Coverage support is assistance with benefit checks and plan-requested paperwork. Approval and payment remain the plan's decisions.
Body Good's prices are service fees for the program described at intake, not the price of medication and not a quote for any individual. Eligibility is determined by a clinician. Medication is a separate cost and is not included in the Body Good service fee. Any clinically appropriate outside laboratory services may also have a separate charge.
This site is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. Intake and checkout happen on joinbodygood.com.
Frequently asked questions
Is Mounjaro insulin?
No. It is a GIP and GLP-1 receptor agonist. It can be used with some diabetes medicines, including insulin, when a clinician prescribes that combination. Combining it with insulin or certain other medicines can increase the risk of low blood sugar, so the clinician may need to adjust care.
Is a prescription guaranteed after an online evaluation?
No. A licensed clinician must evaluate the patient and may decide that Mounjaro is not appropriate. If prescribed, a state-licensed pharmacy dispenses it. Insurance approval and payment are separate decisions made by the health plan.
How can I ask Body Good for a clinical review?
Begin the secure intake to provide information for review. Completing intake does not guarantee a prescription, a particular treatment, insurance approval, or payment.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.